Journey Medical Q2 net revenue up 20% to $18.3M; loss narrows to $7.5M

Journey Medical Corp

2022-Q2 EPS reported -$0.51 revenue$41,587,000

Net revenue $18.3M (+20% YoY), driven by new product launches despite Targadox generic competition.
Net loss $7.5M ($0.43/sh) vs. $11.9M ($1.30/sh) in Q2 2021; Adjusted EBITDA loss $2.6M.
DFD-29 Phase 3 rosacea trials 45% enrolled; top-line data expected H1 2023, NDA in H2 2023.
Settlement with Padagis solidifies exclusivity for QBREXZA, AMZEEQ, ZILXI; supply chain delays resolved.
Tenth dermatology product launch planned in H2 2022; salesforce expanded from 42 to 84 reps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.